DBV Technologies (DBVT) Competitors

DBV Technologies (NASDAQ:DBVT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Which has higher valuation and earnings, DBVT or ELVN?

Enliven Therapeutics has lower revenue, but higher earnings than DBV Technologies. Enliven Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$4.15M	66.00	-$113.92M	-$4.92	-2.03
Enliven Therapeutics	N/A	N/A	-$89.02M	-$1.92	-11.80

Is DBVT or ELVN more profitable?

Enliven Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,249.99%. Enliven Therapeutics' return on equity of -31.84% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,249.99%	-278.24%	-140.54%
Enliven Therapeutics	N/A	-31.84%	-30.09%

Do analysts rate DBVT or ELVN?

DBV Technologies presently has a consensus target price of $14.75, indicating a potential upside of 47.50%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Enliven Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, DBVT or ELVN?

DBV Technologies has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Does the media refer more to DBVT or ELVN?

In the previous week, Enliven Therapeutics had 5 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Enliven Therapeutics and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.28 beat Enliven Therapeutics' score of 0.71 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders have more ownership in DBVT or ELVN?

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 1.4% of DBV Technologies shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats DBV Technologies on 12 of the 15 factors compared between the two stocks.